Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer |
| |
| Authors: | Kimberly S Chiew BSc Heather Shepherd BA Dip HE † Janette Vardy MD PhD FRACP ‡ Martin HN Tattersall MA MSc MD FRCP FRACP § Phyllis N Butow BA PhD Dip Ed MClin Psych MPH ¶ and Natasha B Leighl MD MMSc FRCPC |
| |
| Institution: | Research Assistant, Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, ON, Canada;;Research Assistant, Medical Psychology Research Unit, University of Sydney, Sydney, NSW, Australia;;Medical Oncologist, Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, ON, Canada;;Professor of Cancer Medicine, Medical Psychology Research Unit, University of Sydney, Sydney, NSW, Australia;;Professor of Psychological Medicine, Medical Psychology Research Unit, University of Sydney, Sydney, NSW, Australia;;and Assistant Professor, Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, ON, Canada |
| |
| Abstract: | Objective Treatment decisions in advanced breast cancer are complex, with enhanced quality of life and survival among important treatment goals. Patients with metastatic breast cancer face the decision of whether or not to have chemotherapy, and many wish to be involved in this decision. We report the development and evaluation of a decision aid (DA) designed to assist patients facing this treatment decision. Design and sample Women with metastatic breast cancer (n = 17) and medical oncologists in Australia and Canada (n = 7) were invited to evaluate the DA. Intervention A DA was developed for patients with hormone‐resistant metastatic breast cancer considering chemotherapy. The DA presented options of supportive care, with or without chemotherapy. Potential benefits and side effects of different chemotherapy regimens, and evidence‐based prognostic estimates were described, and a values clarification exercise included. Main outcome measures Patient questionnaires evaluating information and decision involvement preferences, attitudes toward the DA and oncologist feedback regarding attitudes toward the DA. Results Seventeen patients participated; fifteen desired as much information about their illness as possible; sixteen wished to be actively involved in the decision‐making process. The majority rated the DA as highly acceptable, clear and informative, and would recommend it to others facing this treatment decision. Conclusion This is the first DA for patients with advanced metastatic breast cancer considering chemotherapy. A randomized trial is underway to evaluate its role in clinical decision‐making. |
| |
| Keywords: | chemotherapy decision aid metastatic breast cancer shared decision-making |
|
|
